GB9926084D0 - Recombinant fusion molecules - Google Patents

Recombinant fusion molecules

Info

Publication number
GB9926084D0
GB9926084D0 GBGB9926084.6A GB9926084A GB9926084D0 GB 9926084 D0 GB9926084 D0 GB 9926084D0 GB 9926084 A GB9926084 A GB 9926084A GB 9926084 D0 GB9926084 D0 GB 9926084D0
Authority
GB
United Kingdom
Prior art keywords
recombinant fusion
fusion molecules
molecules
recombinant
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9926084.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB9926084.6A priority Critical patent/GB9926084D0/en
Publication of GB9926084D0 publication Critical patent/GB9926084D0/en
Priority to JP2001535412A priority patent/JP2003512860A/en
Priority to BR0015287-0A priority patent/BR0015287A/en
Priority to CA002388955A priority patent/CA2388955A1/en
Priority to AU11584/01A priority patent/AU779719B2/en
Priority to EP00973028A priority patent/EP1226178A1/en
Priority to PCT/GB2000/004216 priority patent/WO2001032714A1/en
Priority to CN00814715A priority patent/CN1399646A/en
Priority to HK02106395.6A priority patent/HK1044956A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
GBGB9926084.6A 1999-11-03 1999-11-03 Recombinant fusion molecules Ceased GB9926084D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB9926084.6A GB9926084D0 (en) 1999-11-03 1999-11-03 Recombinant fusion molecules
JP2001535412A JP2003512860A (en) 1999-11-03 2000-11-03 Recombinant fusion molecule
BR0015287-0A BR0015287A (en) 1999-11-03 2000-11-03 Recombinant fusion molecules
CA002388955A CA2388955A1 (en) 1999-11-03 2000-11-03 Recombinant fusion molecules
AU11584/01A AU779719B2 (en) 1999-11-03 2000-11-03 Recombinant fusion molecules
EP00973028A EP1226178A1 (en) 1999-11-03 2000-11-03 Recombinant fusion molecules
PCT/GB2000/004216 WO2001032714A1 (en) 1999-11-03 2000-11-03 Recombinant fusion molecules
CN00814715A CN1399646A (en) 1999-11-03 2000-11-03 Recombinant fusion molecules
HK02106395.6A HK1044956A1 (en) 1999-11-03 2002-08-29 Recombinant fusion molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9926084.6A GB9926084D0 (en) 1999-11-03 1999-11-03 Recombinant fusion molecules

Publications (1)

Publication Number Publication Date
GB9926084D0 true GB9926084D0 (en) 2000-01-12

Family

ID=10863922

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9926084.6A Ceased GB9926084D0 (en) 1999-11-03 1999-11-03 Recombinant fusion molecules

Country Status (9)

Country Link
EP (1) EP1226178A1 (en)
JP (1) JP2003512860A (en)
CN (1) CN1399646A (en)
AU (1) AU779719B2 (en)
BR (1) BR0015287A (en)
CA (1) CA2388955A1 (en)
GB (1) GB9926084D0 (en)
HK (1) HK1044956A1 (en)
WO (1) WO2001032714A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572908A4 (en) * 2002-02-14 2008-10-22 William J Rutter Chimeric molecules for cleavage in a treated host
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
TW200526778A (en) * 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
JP2008521420A (en) * 2004-11-30 2008-06-26 ノボ ノルディスク アクティーゼルスカブ Methods for producing antibodies
AU2006301846A1 (en) * 2005-10-13 2007-04-19 Akshaya Bio Inc. Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
AU2010222930B2 (en) * 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
CA3032548C (en) 2009-03-10 2023-05-09 Baylor Research Institute Anti-cd40 antibodies and uses thereof
AU2015202777B2 (en) * 2009-11-18 2017-09-14 Agriculture Victoria Services Pty Ltd Angiogenin expression in plants (2)
BR112012012563B1 (en) * 2009-11-18 2021-10-05 Agriculture Victoria Services Pty Ltd METHOD FOR PRODUCING A TRANSFORMED PLANT CELL THAT EXPRESSES AN ANGIOGENIN GENE AND ARTIFICIAL CONSTRUCT CAPABLE OF ALLOWING THE EXPRESSION OF AN ANGIOGENIN GENE IN A PLANT CELL
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
CN106572645A (en) * 2014-06-12 2017-04-19 中央大学校产学协力团 Method for manufacturing transgenic plant producing immunogenic complex proteins and immunogenic complex proteins obtained therefrom
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218889T1 (en) * 1990-11-09 2002-06-15 Stephen D Gillies CYTOKINE IMMUNOCONJUGATES
WO1998036087A1 (en) * 1997-02-13 1998-08-20 American National Red Cross Immunological tolerance to hiv epitopes
PL199659B1 (en) * 1998-02-25 2008-10-31 Merck Patent Gmbh Antibody-based fusion protein featured by prolonged residence in a cireculatory system and method of prolonging its residence time in a circulatory system

Also Published As

Publication number Publication date
CN1399646A (en) 2003-02-26
EP1226178A1 (en) 2002-07-31
BR0015287A (en) 2002-07-09
JP2003512860A (en) 2003-04-08
WO2001032714A1 (en) 2001-05-10
AU1158401A (en) 2001-05-14
HK1044956A1 (en) 2002-11-08
CA2388955A1 (en) 2001-05-10
AU779719B2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
HUP1300326A2 (en) Glp-1 fusion proteins
IL146832A0 (en) Peptides
GB9926084D0 (en) Recombinant fusion molecules
GB9913437D0 (en) Fusion proteins
GB9923177D0 (en) Novel polypeptide
GB9921125D0 (en) Proteins
EP1197556A4 (en) Useful polypeptide
GB9923889D0 (en) Novel polypeptide
EP1147130A4 (en) Alpha-conotoxin peptides
EP1162269A4 (en) Novel polypeptide
EP1159288A4 (en) Alpha-conotoxin peptides
GB9903430D0 (en) Novel proteins
GB9924951D0 (en) Novel polypeptide
EP1179540A4 (en) Novel polypeptide
IL144376A0 (en) Peptides
HK1045173A1 (en) Polypeptide
GB9923890D0 (en) Novel polypeptide
GB9923893D0 (en) Novel polypeptide
GB9920000D0 (en) Polypeptides
GB9924960D0 (en) Novel polypeptide
GB9925115D0 (en) Novel polypeptide
GB9923888D0 (en) Novel polypeptide
EP1151100A4 (en) Tau-conotoxin peptides
IL149355A0 (en) Polypeptide corporation
GB9917995D0 (en) Polypeptide

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)